News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Daily News Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS Todd Neale December 01, 2022
News Daily News Slight Risk of Interstitial Lung Disease Seen With Certain DOACs Todd Neale November 23, 2022
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Daily News Initiative Lowers Unnecessary Aspirin Use in Warfarin Users Todd Neale September 26, 2022
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Daily News Enoxaparin Tops Aspirin for Preventing VTE After Hip or Knee Arthroplasty Todd Neale August 25, 2022
News Daily News Warfarin May Speed Progression of Aortic Stenosis and Worsen Outcomes Todd Neale July 04, 2022
News Daily News Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients L.A. McKeown June 29, 2022
News Conference News EuroPCR 2022 MitraClip Helps for Atrial Functional MR: MITRA-TUNE Michael O'Riordan May 19, 2022
News Conference News HRS 2022 Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients Todd Neale April 29, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022